{"transactions":[{"id":57874,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CONTROLLER"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-03-02T22:03:43.000Z","date":"2023-02-28","kind":"tax_withholding","acquired":false,"shares":11182,"price":154.28,"value":1725158.96,"ownership":{"direct":true},"balance_after":33149,"source":{"system":"sec-edgar","filing":"0001415889-23-003853","document":"form4-03022023_100331.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923003853/form4-03022023_100331.xml","form_type":"4"}},{"id":58477,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CONTROLLER"}}],"security":"Option (right to buy)","published_at":"2023-02-21T23:08:46.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":6752,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,251 on February 16, 2024, 2,251 on February 16, 2025, and 2,251 on February 16, 2026."}],"balance_after":6752,"derivative":{"exercise_price":149.62,"exercise_date":"2024-02-16","expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":6752},"source":{"system":"sec-edgar","filing":"0001415889-23-002941","document":"form4-02212023_110237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002941/form4-02212023_110237.xml","form_type":"4"}},{"id":58476,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CONTROLLER"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:08:46.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":2306,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":44331,"source":{"system":"sec-edgar","filing":"0001415889-23-002941","document":"form4-02212023_110237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002941/form4-02212023_110237.xml","form_type":"4"}},{"id":58475,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CONTROLLER"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:08:46.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":3146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":42025,"source":{"system":"sec-edgar","filing":"0001415889-23-002941","document":"form4-02212023_110237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002941/form4-02212023_110237.xml","form_type":"4"}},{"id":58474,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CONTROLLER"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:08:46.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":3743,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":38879,"source":{"system":"sec-edgar","filing":"0001415889-23-002941","document":"form4-02212023_110237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002941/form4-02212023_110237.xml","form_type":"4"}},{"id":58473,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, CONTROLLER"}}],"security":"Common Stock, $0.01 par value","published_at":"2023-02-21T23:08:46.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":16042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023."}],"balance_after":35136,"source":{"system":"sec-edgar","filing":"0001415889-23-002941","document":"form4-02212023_110237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588923002941/form4-02212023_110237.xml","form_type":"4"}},{"id":68954,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Option (Right to Buy)","published_at":"2022-03-11T22:05:32.000Z","date":"2022-03-09","kind":"exercise","acquired":false,"shares":11682,"price":79.02,"value":923111.64,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":79.02,"exercise_date":"2020-02-21","expiration_date":"2029-02-20","underlying":"Common Stock","underlying_shares":11682},"source":{"system":"sec-edgar","filing":"0001179110-22-002147","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022002147/edgar.xml","form_type":"4"}},{"id":68953,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-11T22:05:32.000Z","date":"2022-03-09","kind":"sale","acquired":false,"shares":6946,"price":150.0008,"value":1041905.5568,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":19094,"source":{"system":"sec-edgar","filing":"0001179110-22-002147","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022002147/edgar.xml","form_type":"4"}},{"id":68952,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-11T22:05:32.000Z","date":"2022-03-09","kind":"sale","acquired":false,"shares":11682,"price":150.0082,"value":1752395.7924,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.04 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":26040,"source":{"system":"sec-edgar","filing":"0001179110-22-002147","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022002147/edgar.xml","form_type":"4"}},{"id":68951,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-11T22:05:32.000Z","date":"2022-03-09","kind":"exercise","acquired":true,"shares":11682,"price":79.02,"value":923111.64,"ownership":{"direct":true},"balance_after":37722,"source":{"system":"sec-edgar","filing":"0001179110-22-002147","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022002147/edgar.xml","form_type":"4"}},{"id":69853,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-03-01T23:11:18.000Z","date":"2022-02-25","kind":"tax_withholding","acquired":false,"shares":7589,"price":149.54,"value":1134859.06,"ownership":{"direct":true},"balance_after":26040,"source":{"system":"sec-edgar","filing":"0001179110-22-001839","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001839/edgar.xml","form_type":"4"}},{"id":70250,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Option (Right to Buy)","published_at":"2022-02-22T22:34:36.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":10945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,649 on February 17, 2023, 3,648 on February 17, 2024, and 3,648 on February 17, 2025."}],"balance_after":10945,"derivative":{"exercise_price":144.54,"exercise_date":"2023-02-17","expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":10945},"source":{"system":"sec-edgar","filing":"0001179110-22-001510","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001510/edgar.xml","form_type":"4"}},{"id":70249,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:34:36.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":2754,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":33629,"source":{"system":"sec-edgar","filing":"0001179110-22-001510","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001510/edgar.xml","form_type":"4"}},{"id":70248,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:34:36.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":3743,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":30875,"source":{"system":"sec-edgar","filing":"0001179110-22-001510","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001510/edgar.xml","form_type":"4"}},{"id":70247,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:34:36.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":1897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":27132,"source":{"system":"sec-edgar","filing":"0001179110-22-001510","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001510/edgar.xml","form_type":"4"}},{"id":70246,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2022-02-22T22:34:36.000Z","date":"2022-02-17","kind":"grant","acquired":true,"shares":8730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022."}],"balance_after":25235,"source":{"system":"sec-edgar","filing":"0001179110-22-001510","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911022001510/edgar.xml","form_type":"4"}},{"id":73939,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Option (right to buy)","published_at":"2021-12-21T22:29:21.000Z","date":"2021-12-20","kind":"exercise","acquired":false,"shares":7180,"price":61.36,"value":440564.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2018-02-16","expiration_date":"2027-02-15","underlying":"Common Stock","underlying_shares":7180},"source":{"system":"sec-edgar","filing":"0001179110-21-011176","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021011176/edgar.xml","form_type":"4"}},{"id":73938,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-12-21T22:29:21.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":11790,"price":128.51,"value":1515132.9,"ownership":{"direct":true},"balance_after":16505,"source":{"system":"sec-edgar","filing":"0001179110-21-011176","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021011176/edgar.xml","form_type":"4"}},{"id":73937,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-12-21T22:29:21.000Z","date":"2021-12-20","kind":"exercise","acquired":true,"shares":7180,"price":61.36,"value":440564.8,"ownership":{"direct":true},"balance_after":28295,"source":{"system":"sec-edgar","filing":"0001179110-21-011176","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021011176/edgar.xml","form_type":"4"}},{"id":92089,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-03-03T01:29:26.000Z","date":"2021-02-28","kind":"tax_withholding","acquired":false,"shares":2392,"price":107.74,"value":257714.08,"ownership":{"direct":true},"balance_after":21115,"source":{"system":"sec-edgar","filing":"0001179110-21-002601","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002601/edgar.xml","form_type":"4"}},{"id":92777,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Option (right to buy)","published_at":"2021-02-22T23:15:55.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":15527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,176 on February 18, 2022, 5,176 on February 18, 2023, and 5,175 on February 18, 2024."}],"balance_after":15527,"derivative":{"exercise_price":105.92,"exercise_date":"2022-02-18","expiration_date":"2031-02-17","underlying":"Common stock","underlying_shares":15527},"source":{"system":"sec-edgar","filing":"0001179110-21-002042","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002042/edgar.xml","form_type":"4"}},{"id":92776,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T23:15:55.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":3743,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":23507,"source":{"system":"sec-edgar","filing":"0001179110-21-002042","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002042/edgar.xml","form_type":"4"}},{"id":92775,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T23:15:55.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":1897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":19764,"source":{"system":"sec-edgar","filing":"0001179110-21-002042","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002042/edgar.xml","form_type":"4"}},{"id":92774,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T23:15:55.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."}],"balance_after":17867,"source":{"system":"sec-edgar","filing":"0001179110-21-002042","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002042/edgar.xml","form_type":"4"}},{"id":92773,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2021-02-22T23:15:55.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":1955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The total shown in this column reflects an update to correct a previous administrative error in the amount of securities beneficially owned by the reporting person."}],"balance_after":17293,"source":{"system":"sec-edgar","filing":"0001179110-21-002042","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911021002042/edgar.xml","form_type":"4"}},{"id":104904,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-05-12T21:44:16.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":60,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 70 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020)."}],"balance_after":17704,"source":{"system":"sec-edgar","filing":"0001179110-20-005829","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005829/edgar.xml","form_type":"4"}},{"id":105309,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-04-24T21:07:16.000Z","date":"2020-03-20","kind":"purchase","acquired":true,"shares":1550,"price":69,"value":106950.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed to correctly indicate the number of shares purchased by the reporting person on March 20, 2020."}],"balance_after":17644,"source":{"system":"sec-edgar","filing":"0001179110-20-005097","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020005097/edgar.xml","form_type":"4/A","original_submission_date":"2020-03-20"}},{"id":106016,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-20T21:34:31.000Z","date":"2020-03-20","kind":"purchase","acquired":true,"shares":750,"price":69,"value":51750.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"This amendment is filed to correct the date of this transaction."}],"balance_after":16844,"source":{"system":"sec-edgar","filing":"0001179110-20-004036","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020004036/edgar.xml","form_type":"4/A","original_submission_date":"2020-03-20"}},{"id":106015,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-20T21:34:31.000Z","date":"2020-03-20","kind":"purchase","acquired":true,"shares":800,"price":67.5,"value":54000.0,"ownership":{"direct":true},"balance_after":16094,"source":{"system":"sec-edgar","filing":"0001179110-20-004036","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020004036/edgar.xml","form_type":"4/A","original_submission_date":"2020-03-20"}},{"id":106014,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-20T21:34:31.000Z","date":"2020-03-18","kind":"purchase","acquired":true,"shares":2200,"price":68.184,"value":150004.8,"ownership":{"direct":true},"balance_after":15294,"source":{"system":"sec-edgar","filing":"0001179110-20-004036","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020004036/edgar.xml","form_type":"4/A","original_submission_date":"2020-03-20"}},{"id":106013,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-20T20:56:12.000Z","date":"2020-03-30","kind":"purchase","acquired":true,"shares":750,"price":69,"value":51750.0,"ownership":{"direct":true},"balance_after":16844,"source":{"system":"sec-edgar","filing":"0001179110-20-004028","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020004028/edgar.xml","form_type":"4"}},{"id":106012,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-20T20:56:12.000Z","date":"2020-03-20","kind":"purchase","acquired":true,"shares":800,"price":67.5,"value":54000.0,"ownership":{"direct":true},"balance_after":16094,"source":{"system":"sec-edgar","filing":"0001179110-20-004028","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020004028/edgar.xml","form_type":"4"}},{"id":106011,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-20T20:56:12.000Z","date":"2020-03-18","kind":"purchase","acquired":true,"shares":2200,"price":68.184,"value":150004.8,"ownership":{"direct":true},"balance_after":15294,"source":{"system":"sec-edgar","filing":"0001179110-20-004028","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020004028/edgar.xml","form_type":"4"}},{"id":106576,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-03-03T21:52:32.000Z","date":"2020-02-28","kind":"tax_withholding","acquired":false,"shares":1941,"price":85.42,"value":165800.22,"ownership":{"direct":true},"balance_after":13094,"source":{"system":"sec-edgar","filing":"0001179110-20-002853","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002853/edgar.xml","form_type":"4"}},{"id":107127,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Option (right to buy)","published_at":"2020-02-24T23:07:30.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":24549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,183 on February 20, 2021, 8,183 on February 20, 2022, and 8,183 on February 20, 2023."}],"balance_after":24549,"derivative":{"exercise_price":93.5,"exercise_date":"2021-02-20","expiration_date":"2030-02-19","underlying":"Common Stock","underlying_shares":24549},"source":{"system":"sec-edgar","filing":"0001179110-20-002139","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002139/edgar.xml","form_type":"4"}},{"id":107126,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:07:30.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":1899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"The total number of securities beneficially owned by the reporting person is updated to correct an administrative error in a previous Form 4."}],"balance_after":15035,"source":{"system":"sec-edgar","filing":"0001179110-20-002139","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002139/edgar.xml","form_type":"4"}},{"id":107125,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:07:30.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":13136,"source":{"system":"sec-edgar","filing":"0001179110-20-002139","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002139/edgar.xml","form_type":"4"}},{"id":107124,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:07:30.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":1075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":12562,"source":{"system":"sec-edgar","filing":"0001179110-20-002139","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002139/edgar.xml","form_type":"4"}},{"id":107123,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2020-02-24T23:07:30.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":2979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020."}],"balance_after":11487,"source":{"system":"sec-edgar","filing":"0001179110-20-002139","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911020002139/edgar.xml","form_type":"4"}},{"id":115118,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2019-07-26T21:03:12.000Z","date":"2019-07-25","kind":"tax_withholding","acquired":false,"shares":613,"price":67.46,"value":41352.98,"ownership":{"direct":true},"balance_after":8508,"source":{"system":"sec-edgar","filing":"0001179110-19-008843","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019008843/edgar.xml","form_type":"4"}},{"id":118122,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2019-03-25T20:34:53.000Z","date":"2019-03-25","kind":"sale","acquired":false,"shares":475,"price":79.69,"value":37852.75,"ownership":{"direct":true},"balance_after":9121,"source":{"system":"sec-edgar","filing":"0001179110-19-004224","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019004224/edgar.xml","form_type":"4"}},{"id":118972,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2019-03-04T21:54:33.000Z","date":"2019-02-28","kind":"tax_withholding","acquired":false,"shares":758,"price":79.41,"value":60192.78,"ownership":{"direct":true},"balance_after":9596,"source":{"system":"sec-edgar","filing":"0001179110-19-003077","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019003077/edgar.xml","form_type":"4"}},{"id":119511,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Option (right to buy)","published_at":"2019-02-22T22:16:05.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":11682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F6","text":"Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,894 on February 21, 2020, 3,894 on February 21, 2021, and 3,894 on February 21, 2022."}],"balance_after":11682,"derivative":{"exercise_price":79.02,"exercise_date":"2020-02-21","expiration_date":"2029-02-20","underlying":"Common Stock","underlying_shares":11682},"source":{"system":"sec-edgar","filing":"0001179110-19-002360","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002360/edgar.xml","form_type":"4"}},{"id":119510,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:16:05.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":10354,"source":{"system":"sec-edgar","filing":"0001179110-19-002360","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002360/edgar.xml","form_type":"4"}},{"id":119509,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:16:05.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":1074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":8869,"source":{"system":"sec-edgar","filing":"0001179110-19-002360","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002360/edgar.xml","form_type":"4"}},{"id":119508,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:16:05.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":7159,"source":{"system":"sec-edgar","filing":"0001179110-19-002360","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002360/edgar.xml","form_type":"4"}},{"id":119507,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11538,"kind":"person","name":"Durkin Brian L","position":1,"cik":"0001756865","reported_name":"Durkin Brian L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Controller"}}],"security":"Common stock, $0.01 par value","published_at":"2019-02-22T22:16:05.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":1213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019."}],"balance_after":5464,"source":{"system":"sec-edgar","filing":"0001179110-19-002360","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000117911019002360/edgar.xml","form_type":"4"}}]}